Hatim Husain, MD
Internal Medicine · San Diego, CANPI 1629234109
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,280,392 of the $2,019,542 with a category attached, or 63.4%. 33 manufacturers reported payments, led by AstraZeneca at 31.6% of the total. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,684 payments — averaging $1199.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$639K
- Johnson & Johnson$245K
- Foundation Medicine, Inc.$193K
- EMD Serono, Inc.$176K
- Jazz Pharmaceuticals Inc.$136K
- Daiichi Sankyo Inc.$103K
- plus $528K from 27 others
Across 45 payments — averaging $13,895 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Sequencing Solutions, Inc.$245K
- Pfizer$196K
- Regeneron$110K
- Takeda Pharmaceuticals U.S.A., Inc.$32K
- Astrazeneca UK Limited$22K
- AstraZeneca$13K
- plus $9K from 1 others
What the payments were for
- Consulting fees$464,89523%
- Speaking & faculty fees$1,280,39263%
- Travel & lodging$237,26112%
- Food & beverage$36,9152%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 536 | $638,718 |
| Johnson & Johnson | 303 | $245,400 |
| Foundation Medicine, Inc. | 53 | $192,796 |
| EMD Serono, Inc. | 129 | $175,718 |
| Jazz Pharmaceuticals Inc. | 87 | $136,241 |
| Daiichi Sankyo Inc. | 80 | $102,561 |
| Regeneron Healthcare Solutions, Inc. | 105 | $91,656 |
| Mirati Therapeutics, Inc. | 47 | $74,591 |
| Merck | 88 | $71,440 |
| Amgen | 59 | $56,559 |
| Blueprint Medicines Corporation | 34 | $36,323 |
| F. Hoffmann-la Roche AG | 11 | $34,215 |
| E.r. Squibb & Sons, L.L.C. | 22 | $26,586 |
| Sanofi | 19 | $24,169 |
| Regeneron | 50 | $19,619 |
| Philips North America LLC | 6 | $17,988 |
| Janssen Global Services, LLC | 12 | $13,020 |
| Rigel Pharmaceuticals, Inc. | 10 | $12,948 |
| Boehringer Ingelheim International GmbH | 5 | $11,566 |
| Janssen Scientific Affairs, LLC | 5 | $7,500 |
| Bayer | 2 | $5,800 |
| Pfizer | 3 | $4,577 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $3,948 |
| Taiho Oncology, Inc. | 1 | $3,500 |
| Immunitybio, Inc. | 1 | $2,500 |
| Catalyst Pharmaceuticals, Inc. | 3 | $2,272 |
| Boehringer Ingelheim | 2 | $2,130 |
| Array Biopharma Inc | 2 | $1,550 |
| Shionogi Inc | 1 | $1,120 |
| Roche Sequencing Solutions, Inc. | 1 | $1,000 |
| Caris MPI, Inc. | 3 | $803 |
| Illumina, Inc. | 1 | $576 |
| Seagen Inc. | 1 | $152 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$292,877
- RYBREVANT$254,257
- FOUNDATIONONE CDX$192,646
- IMFINZI$182,465
- ZEPZELCA$135,667
- LIBTAYO$108,502
- Tepmetko$95,222
- DATROWAY$90,370
- Enhertu$79,359
- KRAZATI$73,960
- KEYTRUDA$54,472
- FOUNDATIONFOCUS$46,271
- FOUNDATIONONE HEME$46,271
- FOUNDATIONONE$46,271
- LUMAKRAS$45,238
- FOUNDATIONONE LIQUID$44,272
- CARVYKTI$38,635
- GAVRETO$30,752
- BAVENCIO$23,651
- HealthTec$17,418
How this compares
$2,019,542 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 227 | $3,635,791 |
| RetevmoSelpercatinib | 23 | $496,142 |
| VitrakviLarotrectinib Sulfate | 11 | $402,698 |
| LorbrenaLorlatinib | 14 | $278,860 |
| AlecensaAlectinib Hcl | 15 | $275,126 |
| LumakrasSotorasib | 12 | $250,020 |
| GilotrifAfatinib Dimaleate | 22 | $221,099 |
| EliquisApixaban | 59 | $35,530 |
| Dexamethasone | 28 | $335 |
| Prochlorperazine Maleate | 29 | $265 |
| Ondansetron OdtOndansetron | 12 | $169 |
| Ondansetron Hcl | 32 | $164 |
| Lidocaine Hcl ViscousLidocaine Hcl | 12 | $135 |
| Oxycodone Hcl | 11 | $58 |
| Folic Acid | 12 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $638,718 | $3,635,791227 claims |
| BayerVitrakvi | $5,800 | $402,69811 claims |
| PfizerLorbrena, Eliquis | $4,577 | $314,39073 claims |
| AmgenLumakras | $56,559 | $250,02012 claims |
| Boehringer IngelheimGilotrif | $2,130 | $221,09922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Diego
- Steven EdelmanSan Diego$863K
- Christian RamersSan Diego$675K
- Adam ZweigSan Diego$421K
- James BreitmeyerSan Diego$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.